Search in:

ClinicoEconomics and Outcomes Research Volume 7, 2015 - Issue

Submit an article Journal homepage

Open access

125

Views

CrossRef citations to date

Altmetric

Original Research

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

Josep Darbà1 Department of Economics, Universitat de Barcelona, Barcelona, SpainCorrespondence[email protected]

Lisette Kaskens2 BCN Health Economics and Outcomes Research SL, Barcelona, Spain

Francesc Sorio Vilela3 Amgen SA, Barcelona, Spain

Mickael Lothgren4 Amgen (Europe) GmbH, Zug, Switzerland

Pages 105-117 | Published online: 09 Feb 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (14)

Thierry Thomas, Florence Tubach, Geoffray Bizouard, Anne Crochard, Frédérique Maurel, Laure Perrin, Cédric Collin, Christian Roux & Julien Paccou. (2022) The Economic Burden of Severe Osteoporotic Fractures in the French Healthcare Database: The FRACTOS Study . Journal of Bone and Mineral Research 37:10, pages 1811-1822.
Crossref

Y. W. Choo, N. A. Mohd Tahir, M. S. Mohamed Said, S. C. Li & M. Makmor Bakry. (2022) Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia. Osteoporosis International 33:9, pages 1909-1923.
Crossref

Y. Wan, F. Zeng, H. Tan, Y. Lu, Y. Zhang, L. Zhao & R. You. (2022) Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review. Osteoporosis International 33:5, pages 979-1015.
Crossref

Marta Osca-Guadalajara, Javier Díaz-Carnicero, Silvia González-de-Julián & David Vivas-Consuelo. (2021) Markov Models for Economic Evaluation in Osteoporosis Treatment. Mathematics 9:18, pages 2331.
Crossref

Nannan Li, Dennis Cornelissen, Stuart Silverman, Daniel Pinto, Lei Si, Ingrid Kremer, Sandrine Bours, Robin de Bot, Annelies Boonen, Silvia Evers, Joop van den Bergh, Jean-Yves Reginster & Mickaël Hiligsmann. (2020) An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis. PharmacoEconomics 39:2, pages 181-209.
Crossref

Haoyi Zheng, Haitao Feng, Wenzhong Zhang, Yantao Han & Wenwen Zhao. (2020) Targeting autophagy by natural product Ursolic acid for prevention and treatment of osteoporosis. Toxicology and Applied Pharmacology 409, pages 115271.
Crossref

Md Azharuddin, Mohammad Adil, Rashid Ali Khan, Pinaki Ghosh, Prem Kapur & Manju Sharma. (2020) Systematic evidence of health economic evaluation of drugs for postmenopausal osteoporosis: A quality appraisal. Osteoporosis and Sarcopenia 6:2, pages 39-52.
Crossref

A. Svedbom, P. Hadji, E. Hernlund, R. Thoren, E. McCloskey, R. Stad & B. Stollenwerk. (2019) Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom. Osteoporosis International 30:9, pages 1745-1754.
Crossref

Pilar Sáez-López, Iñigo Etxebarria-Foronda, Maria Pilar Mesa Lampre, Noelia Alonso García & Natalia Sánchez Hernández. (2019) Efficacy, cost, and aspects to take into account in the treatment of osteoporosis in the elderly. Revista Española de Geriatría y Gerontología 54:3, pages 156-167.
Crossref

Paige Morizio, Jena I. Burkhart & Sachiko Ozawa. (2018) Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients. Annals of Pharmacotherapy 52:10, pages 1031-1041.
Crossref

Emma D. Deeks. (2018) Denosumab: A Review in Postmenopausal Osteoporosis. Drugs & Aging 35:2, pages 163-173.
Crossref

Xiaoqing Ma, Zhongyang Xu, Shaofeng Ding, Guangkun Yi & Qian Wang. (2017) Alendronate promotes osteoblast differentiation and bone formation in ovariectomy‑induced osteoporosis through interferon‑β/signal transducer and activator of transcription 1 pathway. Experimental and Therapeutic Medicine.
Crossref

A. J. FarrierL. C. Sanchez FrancoA. ShoaibV. GulatiN. JohnsonC. E. UzoigweM. Z. Choudhury. (2016) New anti-resorptives and antibody mediated anti-resorptive therapy. The Bone & Joint Journal 98-B:2, pages 160-165.
Crossref

. (2015) Denosumab cost effective in women with osteoporosis. PharmacoEconomics & Outcomes News 722:1, pages 11-11.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

Articles from other publishers (14)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

Citations (14)

Articles from other publishers (14)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date